
Yiran Meng
@yrmeng
Epigenetics. Stem cell. Hematology. Immunology. @UniofOxford, @MRC_WIMM, @MRC_MHU.
ID: 303259220
22-05-2011 15:20:44
101 Tweet
63 Followers
112 Following

A neoadjuvant treatment regimen of anti-PD-L1 #immunotherapy followed by anti-PD-L1 + chemotherapy was well tolerated and led to pathologic response rate of 70% in patients with resectable #GastricCancer or GEJ adenocarcinoma Myriam Chalabi The Netherlands Cancer Institute nature.com/articles/s4159…













📣Excited to share our new study in Nature Medicine that Kexin Huang , Marinka Zitnik, and I have been working on for the last four years! TxGNN is a graph-based foundation model for zero- shot drug repurposing that can find therapies for diseases with zero treatment options.


Neoantigen immunogenicity landscapes and evolution of tumor ecosystems during immunotherapy with nivolumab Nature Medicine Timothy Chan Nadeem Riaz nature.com/articles/s4159…





